CCL2 and metabolic dysfunction-associated steatohepatitis: Gemcabene 100 and 300 mg/kg treated mice significantly down-regulated MCP-1 mRNA expression levels compared with the vehicle-treated NASH mice (1.7 ± 0.7 and 1.6 ± 0.7, respectively, versus 3.6 ± 1.7), and higher than telmisartan (2.1 ± 1.0).